Search
Insulet Corp
PODDAdd to Watchlist
157.740USD
-0.510-0.32%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
10.93BMarket Cap
36.59P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.32%
5 Days
+13.51%
1 Month
+8.83%
6 Months
-45.11%
Year to Date
-44.50%
1 Year
-49.62%
Key Figures
158.220Open
160.700High
1.56MVolume
36.59P/E TTM
19.25P/E Dynamic
--Dividend TTM
2.25%Turnover Ratio
158.250Prev. Close
156.730Low
182.86MTurnover
26.12P/E Static
8.39P/B
0.00%Div Yield TTM
9.31%ROA
354.88052wk High
0.80Volume Ratio
418.30MNet Profit
69.26MShares
4.3105EPS TTM
1.14Beta
23.00%ROE
140.63052wk Low
2.51%Amplitude
69.45%Gross Margin
10.93BMarket Cap
4.36Reward/Risk
2.10%Risk Rate
TradingKey Stock Score of Insulet Corp
Currency: USD Updated: 2026-06-29Key Insights
Insulet Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 24 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 257.35.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Insulet Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
48°C
Very Low
Very High
Positive
Insulet Corp Highlights
StrengthsRisks
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 59.57% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.71B.
Undervalued
The company’s latest PE is 36.59, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 73.18M shares, decreasing 2.16% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.02.
Analyst Rating
Based on
29
analysts
Buy
Current Rating
257.351
Target Price
+62.62%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Insulet Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Insulet Corp Info
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Ticker SymbolPODD
CompanyInsulet Corp
CEOMcevoy (Ashley)
Websitehttps://www.omnipod.com
Related Instruments
-1.97%
-1.34%
-1.50%
+0.31%
-1.73%
-0.74%
-0.71%
-0.09%
+0.08%
-1.83%
-1.45%
-1.76%
-1.57%
+0.44%
+1.90%
+1.33%
-0.49%
-2.82%
+3.97%
-2.31%Popular Instruments
52290.500
+137.300 (+0.26%)
29859.500
+151.800 (+0.51%)
7453.300
+21.100 (+0.28%)
15579.000
+128.000 (+0.83%)
70129.000
-345.000 (-0.49%)
6312.200
+56.400 (+0.90%)
70.491
+0.175 (+0.25%)
281.740
-2.040 (-0.72%)
194.970
+2.440 (+1.27%)
4031.350
+15.760 (+0.39%)
FAQs
What is the current price of Insulet Corp (PODD)?
The current price of Insulet Corp (PODD) is 157.74.
What is the symbol of Insulet Corp?
The ticker symbol of Insulet Corp is PODD.
What is the 52-week high of Insulet Corp?
The 52-week high of Insulet Corp is 354.88.
What is the 52-week low of Insulet Corp?
The 52-week low of Insulet Corp is 140.63.
What is the market capitalization of Insulet Corp?
The market capitalization of Insulet Corp is 10.93B.
Is Insulet Corp (PODD) currently rated as Buy, Hold, or Sell?
According to analysts, Insulet Corp (PODD) has an overall rating of Buy, with a price target of 257.35.
What is the Earnings Per Share (EPS TTM) of Insulet Corp (PODD)?
The Earnings Per Share (EPS TTM) of Insulet Corp (PODD) is 3.51.
